Added to YB: 2026-09-28
Pitch date: 2026-09-23
ABCL [bullish]
AbCellera Biologics Inc.
+5.66%
current return
Author Info
No bio for this author
Company Info
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Market Cap
$4.0B
Pitch Price
$12.02
Price Target
N/A
Dividend
N/A
EV/EBITDA
-19.15
P/E
-22.56
EV/Sales
54.17
Sector
Life Sciences Tools and Services
Category
growth
Abcellera
ABCL (hold): Holding as the T-cell engager platform begins validating AbCellera’s reusable biologics infrastructure through partnerships with AbbVie, Vertex and Jazz. The Jazz deal provides $84M in near-term upfront payments, over $2B in potential downstream payments plus royalties, with options taking potential value above $4B. ABCL575 and ABCL635 remain unproven, with key readouts pending.
Read full article (3 min)